Arvind Utchanah
Director of Finance/CFO bij KNIGHT THERAPEUTICS INC.
Vermogen: 90 237 $ op 29-02-2024
Profiel
Currently, Arvind Utchanah occupies the position of Chief Financial Officer for Knight Therapeutics, Inc.
In his past career Mr. Utchanah held the position of Director-Finance, Accounting & Financial Planning at Paladin Labs, Inc.
He received an undergraduate degree from McGill University and a graduate degree from Concordia University.
Bekende belangen in openbare bedrijven
Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
---|---|---|---|---|
15-03-2024 | 22 475 ( 0.02% ) | 90 237 $ | 29-02-2024 |
Actieve functies van Arvind Utchanah
Bedrijven | Functie | Begin |
---|---|---|
KNIGHT THERAPEUTICS INC. | Director of Finance/CFO | 30-03-2020 |
Eerdere bekende functies van Arvind Utchanah
Bedrijven | Functie | Einde |
---|---|---|
PALADIN LABS INC. | Director of Finance/CFO | 01-06-2016 |
Opleiding van Arvind Utchanah
McGill University | Undergraduate Degree |
Concordia University | Graduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Beursgenoteerde bedrijven | 1 |
---|---|
KNIGHT THERAPEUTICS INC. | Health Technology |
Bedrijven in privébezit | 1 |
---|---|
Paladin Labs, Inc.
Paladin Labs, Inc. Pharmaceuticals: MajorHealth Technology Paladin Labs Inc. operates as pharmaceutical company. It engages in developing, acquiring, in-licensing, marketing, and distributing innovative pharmaceutical products in Canada and internationally. The firm's products include Abstral, GlucaGen, Metadol, Plan B, Pennsaid, Seasonale, Testim, Twinject, Dexedrin, Tridural, and Trelstar. The company was founded by Jonathan Ross Goodman and Mark Beaudet on February 25, 1983 and is headquartered in Montreal, Canada. | Health Technology |